<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573336</url>
  </required_header>
  <id_info>
    <org_study_id>15792</org_study_id>
    <secondary_id>2013-004768-72</secondary_id>
    <nct_id>NCT03573336</nct_id>
  </id_info>
  <brief_title>Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis</brief_title>
  <acronym>VILLENDO</acronym>
  <official_title>A Randomized, Double-blind, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Two Different Doses of Vilaprisan (BAY1002670) Versus Placebo in Women With Symptomatic Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy and safety of two doses of
      vilaprisan compared to placebo in women with symptomatic endometriosis.

      The secondary objective of this study is to evaluate the safety and tolerability of two
      different doses of vilaprisan in women with symptomatic endometriosis.

      With the implementation of protocol amendment 8, no new subjects will be enrolled. The
      objectives above cannot be reached as only limited data is available from subjects recruited
      before the temporary pause.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in the subject's 7-day mean 'worst pain' from baseline to month 3</measure>
    <time_frame>Month 3 of the first 24 weeks treatment period</time_frame>
    <description>Measured on a series of 0-10 Numerical Rating Scale named ESD (Endometriosis Symptom Diary). Lower scores correspond to lower level of pain, higher scores correspond to higher level of pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with an improvement of the subject's mean 'worst pain' on bleeding days from baseline with no increase in rescue pain medication use</measure>
    <time_frame>Month 3</time_frame>
    <description>Measured on a series of 0-10 Numerical Rating Scale named ESD (Endometriosis Symptom Diary). Lower scores correspond to lower level of pain, higher scores correspond to higher level of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with an improvement of the subject's mean 'worst pain' on non-bleeding days from baseline with no increase in rescue pain medication use</measure>
    <time_frame>Month 3</time_frame>
    <description>Measured on a series of 0-10 Numerical Rating Scale named ESD (Endometriosis Symptom Diary). Lower scores correspond to lower level of pain, higher scores correspond to higher level of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with adverse events</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of clinical significant abnormal of endometrial histology</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of clinical significant abnormal of ultrasound examinations</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of clinical significant abnormal of bone mineral density</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of clinical significant abnormal of laboratory parameters</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Vilaprisan (BAY1002670) 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vilaprisan (BAY1002670) 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilaprisan (BAY1002670)</intervention_name>
    <description>Intake orally, once daily</description>
    <arm_group_label>Vilaprisan (BAY1002670) 2 mg</arm_group_label>
    <arm_group_label>Vilaprisan (BAY1002670) 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Intake orally, once daily</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Pre-menopausal women 18 years (inclusive) and above at the time of Visit 1

          -  Women with endometriosis confirmed by laparoscopy or laparotomy OR diagnosed based on
             imaging

          -  Moderate to severe endometriosis-associated pelvic pain (EAPP)

          -  Adherence to screening period diary entries

          -  Willingness to use only standardized pain medication if needed

          -  Good general health (except for findings related to endometriosis)

          -  Normal or clinically insignificant cervical cytology not requiring further follow-up

          -  An endometrial biopsy performed at the screening phase without significant
             histological disorder

          -  Use of an acceptable non-hormonal method of contraception

          -  Willingness / ability to comply with electronic diary entry for the duration of study
             participation

        Exclusion Criteria:

          -  Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation
             before Visit 1)

          -  Hypersensitivity to any ingredient of the study treatments

          -  Laboratory values outside the inclusion range before randomization, and considered
             clinically relevant

          -  Any diseases or conditions that can compromise the function of the body systems and
             could result in altered absorption, excessive accumulation, impaired metabolism, or
             altered excretion of the study drug including elevated liver enzymes

          -  Any diseases or conditions that might interfere with the conduct of the study or the
             interpretation of the results

          -  Undiagnosed abnormal genital bleeding

          -  Abuse of alcohol, drugs, or medicines (e.g. laxatives) as evaluated by the
             investigator

          -  Use of other treatments that might interfere with the conduct of the study or the
             interpretation of the results

          -  Endometriosis-specific treatments for symptom relief except rescue pain medication
             according to protocol

          -  Simultaneous participation in another clinical trial with investigational medicinal
             product(s). Participation in another trial prior to study entry that might have an
             impact on the study objectives, at the discretion of the investigator

          -  Inability to cooperate with the study procedures for any reason

          -  Previous assignment to treatment (e.g. randomization) during this study (allowing
             previously randomized subjects to be re-included into the study may lead to bias)

          -  Hypersensitivity to any ingredient of standardized pain medication

          -  Wish for pregnancy during the study

          -  Regular use of pain medication due to other underlying diseases

          -  Non-responsiveness of EAPP to GnRH-a
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Office of Dr. James A. Simon, MD</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helix Biomedics, LLC</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solutions Through Advanced Research, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Research Associates LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research - Morehead City</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Campus IV</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KABEG Landeskrankenhaus Villach</name>
      <address>
        <city>Villach</city>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital-Riverside Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique OVO</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4P 2S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynekologie MEDA s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GynCare MUDr. Michael Svec s.r.o.</name>
      <address>
        <city>Plzen</city>
        <zip>326 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VL-Medi Oy</name>
      <address>
        <city>Helsinki</city>
        <zip>00260</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Satakunnan keskussairaala</name>
      <address>
        <city>Pori</city>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U.I. Verona</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokeidai Memorial Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishikawa Prefectural Central Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kumamoto Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyama Prefectural Central Hospital</name>
      <address>
        <city>Toyama</city>
        <zip>930-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Chodzki</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <disposition_first_submitted>March 17, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>March 31, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 6, 2020</disposition_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

